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Abstract 
Purpose: To investigate the effects of anthelminthic drug niclosamide in renal cell carcinoma (RCC) and the underly-
ing mechanisms of its action.
Methods: The effects of niclosamide on the proliferation and apoptosis of RCC cells were examined in vitro and 
in vivo by using MTS, colony formation assay, flow cytometry and xenograft cancer mouse model. Mechanism studies 
were performed by analyzing Wnt/β-catenin signaling and mitochondrial functions in a panel of RCC cell lines.
Results: We show that niclosamide effectively targets two RCC cell lines through inhibiting proliferation and 
anchorage-independent colony formation, and inducing apoptosis. It also enhances the inhibitory effects of chemo-
therapeutic drug cisplatin in two independent in vivo RCC xenograft mouse models. Mechanistically, niclosamide 
decreases β-catenin levels and therefore suppresses Wnt/β-catenin activities. Overexpression of β-catenin partially 
reverses the inhibitory effects of niclosamide in RCC cells, demonstrating that besides β-catenin, other mechanisms 
are involved in niclosamide’s anti-cancer activity. Indeed, we further show that niclosamide induces mitochondrial 
dysfunctions as shown by the decreased level of mitochondrial membrane potential and respiration, resulting in 
decreased ATP levels and increased reactive oxygen species (ROS) levels.
Conclusions: Our findings support the inhibitory effects of niclosamide in cancer and provide better understanding 
on its underlying mechanism. Our data suggests that niclosamide is a useful addition to the treatment armamen-
tarium for RCC.
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Background
Renal cell carcinoma (RCC) is an epithelial tumour 
derived from the proximal tubules of nephrons (Thoenes 
et  al. 1986). It is the most aggressive type of genitouri-
nary cancer and resistant to chemotherapy, radiotherapy 
and targeted therapy (Bukowski 1997; Kanesvaran and 
Tan 2014). The molecular mechanisms leading to RCC 
development, progression and resistance are complex 
and involve abnormal genetic modifications and aberrant 
activation of oncogenic signaling pathways, such as Wnt/
β-catenin, phosphatidylinositol 3-kinases (PI3  K)/Akt 
and hepatocyte growth factor (HGF)/c-MET pathways 
(Zhou et al. 2015; Cojocaru et al. 2015). The identification 
of therapeutic agents that targets these oncogenic path-
ways may have the potential to improve the efficacy for 
RCC treatment.
Niclosamide is an anthelmintic drug especially used for 
the treatment of cestodes infection (Tanowitz et al. 1993). 
It kills parasites through inhibiting mitochondrial oxida-
tive phosphorylation (Weinbach and Garbus 1969). How-
ever, niclosamide has been recently identified as a novel 
type of anti-cancer drug. It suppresses growth of several 
tumor cell lines (Arend et al. 2014; Osada et al. 2011; Lu 
et  al. 2011; Khanim et  al. 2011). When niclosamide is 
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combined with conventional chemotherapeutic drugs, 
the combination showed significant enhanced anti-
cancer effects (Liu et  al. 2016). Several work highlight 
niclosamide as a potent Wnt/β-catenin inhibitor and that 
inhibition of β-catenin signalling is the mechanism of its 
action on cancer (Arend et al. 2014; Osada et al. 2011; Lu 
et  al. 2011; Chowdhury et  al. 2016). Others believe that 
niclosamide’s anti-cancer activity is mediated through 
mitochondria, NF-κB pathway or androgen receptor sig-
nalling (Khanim et al. 2011; Liu et al. 2016; Jin et al. 2010). 
Nevertheless, the molecular mechanisms of niclosamide 
in cancer are not well defined.
The potent inhibitory effects on a panel of tumor cell 
lines and its known cytotoxicity as well as pharmacoki-
netic profiles make niclosamide an attractive candidate 
for cancer treatment. Although its anti-tumor activities 
had been reported in various tumors, the effectiveness of 
niclosamide in RCC is unknown. In this study, we investi-
gated the effects of niclosamide and its underlying mech-
anisms in RCC cells using in vitro cellular culture system 
and in  vivo xenograft mouse tumor model. To further 
explore the application potential of niclosamide in RCC, 
the combinatory effects of niclosamide and chemothera-
peutic drugs were examined.
Methods
Cells and drugs
Human renal carcinoma cell lines, A-498 and SW-839 
were purchased from American Type Culture Collection. 
Cells were cultured in Eagle’s Minimal Essential Media 
(MEM) supplemented with a final concentration of 10 % 
fetal bovine serum (Hyclone, UK) and 100 u/ml penicil-
lin–streptomycin (Invitrogen, US). Niclosamide (BioVi-
sion Inc. US) and cisplatin (Sigma, US) were dissolved in 
DMSO and water, respectively.
MTS proliferation assay
Cells at ten thousands were seeded in 96 well plates over-
night. The next day, cells were treated with niclosamide 
for 72 h. 20 µl of tetrazolium compound [3-(4,5-dimeth-
ylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sul-
fophenyl)-2H-tetrazolium, inner salt; MTS] was added 
to each well and incubated for 2 h. The absorbance was 
measured at 490 nm.
Annexin V flow cytometry analysis
Cells at 1 × 105 were seeded at 12 well plate and treated with 
niclosamide for 72 h. After treatment, cells were detached 
using trypsin (Invitrogen) and stained with Annexin 
V-FITC (BD Pharmingen, US). The stained cells were ana-
lysed by flow cytometry on a Beckman Coulter FC500 and 
a minimum of 5000 events were counted. The percentage of 
Annexin V-positive cells was determined by CXP software.
Colony formation assay
A bottom layer of a final concentrating of 0.7  % Bacto 
agar was prepared in 12 well plates. Cells at 1000 together 
with niclosamide were seeded in a plate with a top layer 
of 0.3 % Bacto agar. 100 µl of culture medium was added 
to the top layer and replaced with fresh one twice a week. 
After 10–14 days, the colonies were stained with crystal 
violet and the number of colonies were scored.
Western blot (WB) analyses
Total protein were lysed by using radioimmunoprecipi-
tation assay (RIPA) buffer (Invitrogen). Equal amount of 
proteins were resolved using denaturing SDS–PAGE and 
analyzed by WB using antibodies recognizing β-catenin 
and β-actin (Santa Cruz Biotechnology Inc, US).
Mitochondrial metabolic assay
Cells were treated with different concentrations of 
niclosamide for 24  h prior to mitochondrial function 
analysis. To measure mitochondrial membrane poten-
tial, cells were stained with 5,5′,6,6′-tetrachloro-1,1′,3,3′-
tetraethyl benzimidazolylcarbocyanine iodide (JC-1, 
Invitrogen) and analysed by flow cytometry on a Beck-
man Coulter FC500. Oxygen Consumption Rate (OCR) 
was measured using a Seahorse XF24 extracellular flux 
analyser (Seahorse Bioscience, US) according to manu-
facturer’s instructions. Analyses were performed at 
basal conditions. ATP levels were measured by ATPlite 
Luminiescent Assay kit (Perkin Elmer, US) according to 
the manufacturer’s protocol. To measure intracellular 
ROS, cells were incubated with 10  µM CM-H2DCFDA 
(Invitrogen) and absorbance at ex/em of 495/525  nm 
were measured.
Plasmid transfection
Transfections were carried out in A-498 and SW-839 cells 
by using nucleofection (Lonza, US). The M50 Super 8× 
TOPFlash plasmid (a kind gift from Dr. Randall Moon) 
(Veeman et  al. 2003) and Luciferase Reporter Assay 
System (Promega, US) were used for TOPflash assay. 
For β-catenin overexpression, cells were transfected 
with 1.5 μg pcDNA, or pcDNA-β-cat (human β-catenin 
pcDNA3 plasmid, a kind gift from Dr. Eric Fearon) (Kol-
ligs et al. 1999). At 24 h after transfection, cells were used 
to perform WB or rescue experiments.
RCC xenograft in SCID mouse
The animal experiments were approved by the Institu-
tional Animal Care and Use Committee of Xiangyang 
Central Hospital. SCID mice (Biocytogen Inc, China) 
were subcutaneously injected with 100 µl mixture (1:1) of 
10 million cells and Matrigel (BD Biosciences, US). The 
mice were treated with vehicle control, intraperitoneal 
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niclosamide at 10 mg/kg, cisplatin at 50 mg/kg or com-
bination of both. Tumour volume were measured every 
three days.
Statistical analyses
The data are expressed as mean and standard deviation. 
Statistical analyses were performed by unpaired Stu-
dent’s t test. p value <0.05 were considered statistically 
significant.
Results
Niclosamide is active against renal carcinoma cells
Two human RCC cell lines, A-498 and SW-839, were 
used in this study. These cell lines were treated with 
various concentrations of niclosamide for 3 days prior to 
MTS and Annexin V analysis. We found that niclosamide 
significantly inhibited proliferation in a dose-dependent 
manner in A-498 and SW-839 cells (Fig.  1a). In addi-
tion, niclosamide dose-dependently induced apoptosis 
of these two cell lines (Fig. 1b). Anchorage-independent 
growth in soft agar is often predictive of tumorigenicity 
as colonies formed in soft agar are from cells displaying 
both highly proliferative and invasive phenotypes (Gao 
et al. 2005). We found that niclosamide was also effective 
in inhibiting anchorage-independent growth of RCC cells 
(Fig. 1c, d). The IC50 of niclosamide on A-498 is similar to 
the one in SW-839, suggesting that niclosamide is active 
against RCC cells regardless of their cellular origin.
The inhibitory effects of niclosamide on renal carcinoma 
cells are partially through suppressing Wnt/β‑catenin 
pathway
Several studies have demonstrated the potent inhibi-
tory effects of niclosamide on Wnt/β-catenin signal-
ing pathway in various types of cancers (Arend et  al. 
2014; Osada et al. 2011; Lu et al. 2011). Consistent with 
these findings, our work demonstrated that niclosamide 
decreased levels of intracellular β-catenin in RCC cells 
(Fig. 2a). To confirm the inhibitory effect of niclosamide 
on Wnt/β-catenin signaling in RCC cells, we performed 
Fig. 1 Niclosamide inhibits proliferation and anchorage-independent colony formation and induces apoptosis in RCC cell lines. a Niclosamide 
decreases proliferation of A-498 and SW-839 cells. b Niclosamide induces apoptosis of A-498 and SW-839. c Representative images taken at 14 days 
of an anchorage-independent colony formation assay. d Quantification of colonies show the dose-dependent inhibitory effect of niclosamide on 
colony formation in RCC cells. *p < 0.05, compared to control
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Wnt/β-catenin reporter assay by transiently transfected 
with TOPFlash plasmid. Niclosamide dose-dependently 
inhibited the TOPFlash activity in RCC cells (Fig.  2b), 
which correlates well with the decreased levels of 
β-catenin in RCC cells exposed to niclosamide (Fig. 2a).
To investigate whether β-catenin stabilization can abol-
ish the effects of niclosamide, we rescued β-catenin lev-
els by overexpressing β-catenin in RCC cells (Fig.  2c). 
In β-catenin-overexpressing A-498 and SW-839 cells, 
niclosamide is less effective in inhibiting proliferation 
and colony formation, and inducing apoptosis compared 
to control cells (Fig. 2d–f). These data demonstrate that 
inhibition of Wnt/β-catenin signalling is the molecular 
mechanism of niclosamide’s action in RCC cells. It is also 
noted that β-catenin-overexpression failed to completely 
rescue the inhibitory effects of niclosamide, suggesting 
that other mechanisms are involved for the observed bio-
logical effects of niclosamide in RCC.
Niclosamide induces mitochondrial dysfunctions
It is known that niclosamide kills the tapeworm 
through inhibiting oxidative phosphorylation (Wein-
bach and Garbus 1969). Khanim et  al. recently dem-
onstrated that niclosamide targets mitochondria in 
multiple myeloma cells by reducing free light chain 
production (Khanim et al. 2011). We therefore investi-
gated the effects of niclosamide on mitochondrial func-
tions in RCC cells.
We found that niclosamide decreased mitochondrial 
membrane potential at the same effective concentra-
tions (e.g., 1, 5, and 10  µM) that inhibits proliferation 
and induces apoptosis (Fig. 3a). In addition, niclosamide 
significantly inhibited OCR, decreased ATP levels and 
increased ROS levels in RCC cells (Fig.  3b–d). Taken 
together these data show that niclosamide impairs mito-
chondrial functions to induce an energy crisis and oxida-
tive damage in RCC cells.
Fig. 2 Niclosamide inhibits Wnt/β-catenin signaling in RCC cells. a Niclosamide decreases intracellular β-catenin levels in A-498 and SW-839 cells. 
Cells were treated with niclosamide for 24 h prior to WB analysis. b Niclosamide inhibits TOPflash activation. RCC cells transfected with TOPflash 
plasmid were treated with niclosamide as indicated. RLU, relative light units. c β-Catenin level is increased n A-498 and SW-839 cells transfected with 
β-catenin overexpression plasmid. Overexpression of β-catenin partially rescued the effects of niclosamide in inhibiting proliferation (d) and colony 
formation (e) and inducing apoptosis (f) in RCC cells. *p < 0.05, compared to control or p-Vector
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Niclosamide inhibits growth of renal carcinoma in vivo 
and enhances the effects of chemotherapeutic drug
We next tested the in vivo efficacy of niclosamide and inves-
tigated whether its combination with cisplatin (common 
chemotherapeutic drug) resulted in greater efficacy than 
single drug alone. We established two RCC xenograft mouse 
models by subcutaneous injection of A-498 or SW-839 cells 
into nude mice. When mice tumor reached 200 mm3, mice 
were treated with vehicle control, intraperitoneal niclosa-
mide, cisplatin or combination of niclosamide and cisplatin 
for 3 weeks. No significant body weight loss and abnormal 
behavior in all groups (data not shown) indicate that the 
mice tolerated the treatment well. We further show that 
niclosamide inhibited growth of tumors derived from both 
A-498 and SW-839 cells (Fig. 4). It is noted that niclosamide 
at 10 mg/kg achieved similar efficacy as chemotherapeutic 
drug cisplatin at 40 mg/kg. More importantly, the combina-
tion of niclosamide and cisplatin further inhibited tumor 
growth in both RCC xenograft models (Fig. 4). Our in vivo 
data are consistent with in  vitro data, and confirmed the 
anti-cancer activities of niclosamide in RCC.
Discussion
Current therapies including chemotherapy, radiotherapy 
and targeted therapy have not yielded durable remissions 
in RCC patients (Kanesvaran and Tan 2014; Lisa et  al. 
2016). There are many ongoing research efforts to dis-
cover drugs to eradicate RCC cells. The discovery, devel-
opment and registration of novel compounds can be a 
long and laborious process. An alternative to new drug 
development is drug repositioning. For example, tha-
lidomide has been successfully repurposed for myeloma 
treatment (Mutsaers 2007; Chong and Sullivan 2007). In 
this study, we evaluated anthelmintic drug niclosamide as 
a potential candidate for RCC treatment. We are the first 
to demonstrate the suppression of Wnt/β-catenin and 
induction of mitochondrial dysfunctions in RCC cells by 
niclosamide, leading to proliferation inhibition and cell 
death.
Two cell lines, A-498 and SW-839, selected for dem-
onstration of the biological effects of niclosamide are 
derived from the most frequent clear-cell tumor sub-
type of RCC (accounting for >80 % of all RCCs) (Kovacs 
et  al. 1997). Our study show that niclosamide signifi-
cantly inhibits proliferation and induces apoptosis in 
both A-498 and SW-839 cells (Fig. 1a, b), suggesting the 
therapeutic efficacy of niclosamide in the majority of 
RCCs. Niclosamide also significantly inhibits anchorage-
independent colony formation of RCC cells (Fig.  1c, d), 
further demonstrating its inhibitory effects on RCC sub-
populations with highly proliferative and invasive prop-
erties (Gao et al. 2005). The efficacy of niclosamide have 
Fig. 3 Niclosamide impairs mitochondrial function and induces oxidative stress. Niclosamide decreases mitochondrial membrane potential  
(a), inhibits mitochondrial respiration (b), increases ROS levels (c) and reduces ATP levels (d) in RCC cells. *p < 0.05, compared to control
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been demonstrated in various cancers, such as colon, 
cancer, ovarian cancers and myeloma (Arend et al. 2014; 
Osada et  al. 2011; Khanim et  al. 2011). Our data sup-
ports the previous studies on the inhibitory effects of 
niclosamide in cancer and adds RCC to the growing list 
of niclosamide-targeted cancers.
Consistent with the in vitro data, niclosamide inhibits 
growth of two independent RCC cancer xenograft mouse 
models established by using A-493 and SW-839 cells 
(Fig. 4), confirming its in vivo efficacy. Notably, niclosa-
mide further enhanced the inhibitory effect of cisplatin in 
RCC tumor growth (Fig. 4), demonstrating the synergism 
of niclosamide and chemotherapeutic drugs in RCC. In 
addition, our data show that mice tolerate very well to 
niclosamide at 10  mg/kg given by intraperitoneal injec-
tion (data not shown). Although niclosamide has little 
absorption from gastrointestinal tract, pharmacokinetic 
analysis of niclosamide following oral administration 
in mice by Osada et  al. show the efficient and reliable 
destruction of niclosamide from blood to tumor tis-
sue (Osada et al. 2011). Our data together with previous 
studies suggest that greater absorption of niclosamide 
can be achieved either by drug modifications or by using 
different administration route.
The mechanism of action of niclosamide seems to be in 
a cancer cell-type specific manner. Some have reported 
that niclosamide suppresses Wnt/β-catenin signal-
ling via inducing lipoprotein receptor-related protein-6 
(LRP6) degradation in prostate and breast cancer cells 
(Lu et al. 2011). Others have demonstrated that niclosa-
mide induces free light chain production in myeloma 
cells (Khanim et  al. 2011). We found that niclosamide 
decreased levels of β-catenin and therefore suppressed 
Wnt/β-catenin activities in A-498 and SW-839 cells 
Fig. 4 Niclosamide inhibits RCC tumor growth and enhances the inhibitory effect of cisplatin in vivo. Niclosamide inhibited growth of RCC tumors 
derived from A-498 (a) and SW-839 (b) cells as a single drug. Combination of niclosamide and cisplatin significantly inhibited much more tumor 
growth throughout the duration of treatment in two xenograft RCC models. *p < 0.05, compared to control or single arm
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(Fig.  2a, b). Furthermore, overexpression of β-catenin 
levels partially abolished the inhibitory effects of niclosa-
mide in RCC cells (Fig. 2c–f). These data agree with the 
previous work that niclosamide targets RCC cells through 
inhibiting Wnt/β-catenin signalling pathways. Aberrant 
Wnt/β-catenin signalling pathway caused by APC defi-
ciency or HIF1α play important roles in RCC progression 
(Cojocaru et al. 2015; Majid et al. 2012). Wnt/β-catenin 
signalling pathway has been the target of major drug dis-
covery programs in the past decade. In line with these 
efforts, our work agrees with the essential roles of Wnt/β-
catenin in RCC and further demonstrates that it can be 
effectively targeted by niclosamide.
However, the partial but not complete rescue by 
β-catenin overexpression suggests that other mecha-
nisms of action might be involved in the cells treated with 
niclosamide. Indeed, we found that niclosamide induces 
mitochondrial dysfunctions via decreasing mitochon-
drial membrane potential, OCR and ATP levels (Fig. 3a, 
b, d). A consequence of impaired mitochondrial function 
induced by niclosamide is the increased oxidative dam-
age as shown by the increased levels of ROS (Fig.  3c). 
Targeting cancer metabolism, such as mitochondrial 
metabolism, has recently become an attractive thera-
peutic strategy in cancer due to their unique depend-
ence on oxidative phosphorylation (Jaras and Ebert 2011; 
Loureiro et al. 2013; Moreno-Sanchez et al. 2007; Funes 
et  al. 2007). Various antibiotics or anthelminthic drugs 
that target mitochondria have been reported to be effec-
tive in inhibiting a large panel of cancer cells (Lamb et al. 
2015). Our work together with the previous work suggest 
that induction of mitochondria dysfunctions might be a 
common mechanism of the action of those antibiotics in 
cancers.
In conclusion, our results show that niclosamide 
effectively targets RCC cells through both suppressing 
Wnt/β-catenin signalling and inducing mitochondrial 
dysfunctions. Importantly, niclosamide significantly 
enhances the effect of chemotherapeutic drug cisplatin 
in inhibiting tumour growth in two-independent RCC 
xenograft models. Our findings suggest that niclosamide 
may have utility in treating patients with RCC.
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